OBJECTIVE: Motor signs are functionally disabling features of Huntington disease. Characteristic motor signs define disease manifestation. Their severity and onset are assessed by the Total Motor Score of the Unified Huntington's Disease Rating Scale, a categorical scale limited by interrater variability and insensitivity in premanifest subjects. More objective, reliable, and precise measures are needed which permit clinical trials in premanifest populations. We hypothesized that motor deficits can be objectively quantified by force-transducer-based tapping and correlate with disease burden and brain atrophy. METHODS: A total of 123 controls, 120 premanifest, and 123 early symptomatic gene carriers performed a speeded and a metronome tapping task in the multicenter study TRACK-HD. Total Motor Score, CAG repeat length, and MRIs were obtained. The premanifest group was subdivided into A and B, based on the proximity to estimated disease onset, the manifest group into stages 1 and 2, according to their Total Functional Capacity scores. Analyses were performed centrally and blinded. RESULTS: Tapping variability distinguished between all groups and subgroups in both tasks and correlated with 1) disease burden, 2) clinical motor phenotype, 3) gray and white matter atrophy, and 4) cortical thinning. Speeded tapping was more sensitive to the detection of early changes. CONCLUSION: Tapping deficits are evident throughout manifest and premanifest stages. Deficits are more pronounced in later stages and correlate with clinical scores as well as regional brain atrophy, which implies a link between structure and function. The ability to track motor phenotype progression with force-transducer-based tapping measures will be tested prospectively in the TRACK-HD study.
OBJECTIVE: Motor signs are functionally disabling features of Huntington disease. Characteristic motor signs define disease manifestation. Their severity and onset are assessed by the Total Motor Score of the Unified Huntington's Disease Rating Scale, a categorical scale limited by interrater variability and insensitivity in premanifest subjects. More objective, reliable, and precise measures are needed which permit clinical trials in premanifest populations. We hypothesized that motor deficits can be objectively quantified by force-transducer-based tapping and correlate with disease burden and brain atrophy. METHODS: A total of 123 controls, 120 premanifest, and 123 early symptomatic gene carriers performed a speeded and a metronome tapping task in the multicenter study TRACK-HD. Total Motor Score, CAG repeat length, and MRIs were obtained. The premanifest group was subdivided into A and B, based on the proximity to estimated disease onset, the manifest group into stages 1 and 2, according to their Total Functional Capacity scores. Analyses were performed centrally and blinded. RESULTS: Tapping variability distinguished between all groups and subgroups in both tasks and correlated with 1) disease burden, 2) clinical motor phenotype, 3) gray and white matter atrophy, and 4) cortical thinning. Speeded tapping was more sensitive to the detection of early changes. CONCLUSION: Tapping deficits are evident throughout manifest and premanifest stages. Deficits are more pronounced in later stages and correlate with clinical scores as well as regional brain atrophy, which implies a link between structure and function. The ability to track motor phenotype progression with force-transducer-based tapping measures will be tested prospectively in the TRACK-HD study.
Authors: Sarah A J Reading; Michael A Yassa; Arnold Bakker; Adam C Dziorny; Lisa M Gourley; Venu Yallapragada; Adam Rosenblatt; Russell L Margolis; Elizabeth H Aylward; Jason Brandt; Susumu Mori; Peter van Zijl; Susan S Bassett; Christopher A Ross Journal: Psychiatry Res Date: 2005-09-30 Impact factor: 3.222
Authors: Sarah J Tabrizi; Douglas R Langbehn; Blair R Leavitt; Raymund Ac Roos; Alexandra Durr; David Craufurd; Christopher Kennard; Stephen L Hicks; Nick C Fox; Rachael I Scahill; Beth Borowsky; Allan J Tobin; H Diana Rosas; Hans Johnson; Ralf Reilmann; Bernhard Landwehrmeyer; Julie C Stout Journal: Lancet Neurol Date: 2009-07-29 Impact factor: 44.182
Authors: Stefan Klöppel; Bogdan Draganski; Hartwig R Siebner; Sarah J Tabrizi; Cornelius Weiller; Richard S J Frackowiak Journal: Brain Date: 2009-04-15 Impact factor: 13.501
Authors: Elizabeth H Aylward; Deborah L Harrington; James A Mills; Peggy C Nopoulos; Christopher A Ross; Jeffrey D Long; Dawei Liu; Holly K Westervelt; Jane S Paulsen Journal: J Huntingtons Dis Date: 2013
Authors: Christine Delmaire; Eve M Dumas; Michael A Sharman; Simon J A van den Bogaard; Romain Valabregue; Céline Jauffret; Damian Justo; Ralf Reilmann; Julie C Stout; David Craufurd; Sarah J Tabrizi; Raymund A C Roos; Alexandra Durr; Stéphane Lehéricy Journal: Hum Brain Mapp Date: 2012-03-22 Impact factor: 5.038
Authors: S J A van den Bogaard; E M Dumas; J Milles; R Reilmann; J C Stout; D Craufurd; M A van Buchem; J van der Grond; R A C Roos Journal: AJNR Am J Neuroradiol Date: 2012-01-12 Impact factor: 3.825
Authors: Christopher A Ross; Elizabeth H Aylward; Edward J Wild; Douglas R Langbehn; Jeffrey D Long; John H Warner; Rachael I Scahill; Blair R Leavitt; Julie C Stout; Jane S Paulsen; Ralf Reilmann; Paul G Unschuld; Alice Wexler; Russell L Margolis; Sarah J Tabrizi Journal: Nat Rev Neurol Date: 2014-03-11 Impact factor: 42.937